Background: The Xpert MTB/RIF assay has garnered significant interest as a sensitive and rapid diagnostic tool to improve detection of sensitive and drug resistant tuberculosis. However, most existing ...

Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...

The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of tuberculosis in decades. David L. Cohn This molecular-based test provides a rapid and sensitive ...

Microbiological confirmation of childhood tuberculosis is rare because of the difficulty of collection of specimens, low sensitivity of smear microscopy, and poor access to culture. A new study aimed ...

Cepheid has supported TB testing worldwide for over 15 years. Xpert MTB/RIF, released in 2009 in collaboration with the Foundation for Innovative New Diagnostics (FIND), was a first-of-its-kind ...

FDA Expands Xpert MTB/RIF Test Use The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can ...

Geneva: The World Health Organization announced Thursday it had given a first-ever green light to a test for tuberculosis -- a disease which killed 1.25 million people last year. Xpert MTB/RIF Ultra, ...

During the period from September 2011 to March 2013, a total of 30 TB REACH grants across 24 countries designated funds to procure GeneXpert machines and the Xpert MTB/RIF assay. Of these, a ...

SUNNYVALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new ...